NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - NYSE:NMR - US65535H2085 - ADR
7.14 USD
+0.02 (+0.28%)
7.04 USD
-0.1 (-1.4%)
Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 237 industry peers in the Capital Markets industry. Both the profitability and financial health of NMR have multiple concerns. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
In the past year NMR has reported a negative cash flow from operations.
Each year in the past 5 years NMR has been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
NMR's Return On Assets of 0.60% is on the low side compared to the rest of the industry. NMR is outperformed by 69.62% of its industry peers.
NMR has a Return On Equity (9.82%) which is in line with its industry peers.
With a Return On Invested Capital value of 0.63%, NMR is not doing good in the industry: 70.04% of the companies in the same industry are doing better.
Measured over the past 3 years, the Average Return On Invested Capital for NMR is significantly below the industry average of 7.59%.
The 3 year average ROIC (0.42%) for NMR is below the current ROIC(0.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.63% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
With a Profit Margin value of 7.19%, NMR is not doing good in the industry: 62.87% of the companies in the same industry are doing better.
NMR's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 9.96%, NMR is not doing good in the industry: 67.09% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a Gross Margin (39.95%) which is in line with its industry peers.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
Compared to 1 year ago, NMR has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.27, we must say that NMR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.27, NMR is doing worse than 79.32% of the companies in the same industry.
NMR has a Debt/Equity ratio of 10.44. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 10.44, NMR is not doing good in the industry: 89.45% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.22 indicates that NMR may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.22, NMR is doing worse than 88.19% of the companies in the same industry.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Quick ratio (0.22) than 87.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.52% over the past year.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
The Revenue has grown by 13.94% in the past year. This is quite good.
The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
3.2 Future
The Earnings Per Share is expected to grow by 2.33% on average over the next years.
Based on estimates for the next years, NMR will show a decrease in Revenue. The Revenue will decrease by -6.12% on average per year.
EPS Next Y6.54%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
EPS Next 5YN/A
Revenue Next Year-18.6%
Revenue Next 2Y-9.83%
Revenue Next 3Y-6.12%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.40 indicates a reasonable valuation of NMR.
Based on the Price/Earnings ratio, NMR is valued a bit cheaper than the industry average as 77.22% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.51. NMR is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.04, which indicates a very decent valuation of NMR.
75.95% of the companies in the same industry are more expensive than NMR, based on the Price/Forward Earnings ratio.
NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.53.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.4 | ||
| Fwd PE | 9.04 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than 67.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.81 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.28
PEG (5Y)0.77
EPS Next 2Y1.02%
EPS Next 3Y2.33%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 4.63%, which is a nice return.
Compared to an average industry Dividend Yield of 8.38, NMR has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.38, NMR pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.63% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
33.03% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
7.14
+0.02 (+0.28%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners41.49%
Inst Owner Change-0.63%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.95B
Revenue(TTM)4736.74B
Net Income(TTM)340.74B
Analysts73.33
Price Target7.73 (8.26%)
Short Float %0.04%
Short Ratio2.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.63% |
Yearly Dividend0.26
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.08%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)-0.19%
EPS NY rev (1m)0%
EPS NY rev (3m)1.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.4 | ||
| Fwd PE | 9.04 | ||
| P/S | 0.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.93 | ||
| P/tB | 0.95 | ||
| EV/EBITDA | 22.81 |
EPS(TTM)0.85
EY11.9%
EPS(NY)0.79
Fwd EY11.06%
FCF(TTM)-3.42
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS10.47
BVpS7.67
TBVpS7.51
PEG (NY)1.28
PEG (5Y)0.77
Graham Number12.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.65% | ||
| ROIC | 0.63% | ||
| ROICexc | 0.69% | ||
| ROICexgc | 0.7% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | 0.16 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -0.27 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
EPS Next Y6.54%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
EPS Next 5YN/A
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
Revenue Next Year-18.6%
Revenue Next 2Y-9.83%
Revenue Next 3Y-6.12%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year23818.4%
EBIT Next 3Y525.25%
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A
NOMURA HOLDINGS INC-SPON ADR / NMR FAQ
Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a fundamental rating of 3 / 10 to NMR.
Can you provide the valuation status for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.
What is the profitability of NMR stock?
NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 2 / 10.
How financially healthy is NOMURA HOLDINGS INC-SPON ADR?
The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.
What is the expected EPS growth for NOMURA HOLDINGS INC-SPON ADR (NMR) stock?
The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 6.54% in the next year.